Celecoxib (Celebrex) in the Management of Acute Renal Colic
Status:
Withdrawn
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to quantify the amount Celebrex, a specific cyclooxygenase-2
(COX-2) inhibitor, when used for the management of acute renal colic for a ureteral stone
will:
- reduce pain medication usage
- improve the percentage of spontaneous stone passage
- decrease the time to spontaneous passage, and
- shift the size distribution of stones passed towards larger sizes
Phase:
Phase 4
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute